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ABSTRACT
Parathyroid hormone (PTH) regulates calcium homeostasis and bone remodeling through its cognitive receptor (PTHR). We describe
here a PTHR isoform harboring an in-frame 42-bp deletion of exon 14 (De14-PTHR) that encodes transmembrane domain 7. De14-PTHR
was detected in human kidney and buccal epithelial cells. We characterized its topology, cellular localization, and signaling, as well as its
interactions withPTHR. The C-terminus of the De14-PTHR is extracellular, and cell surface expression is strikingly reduced compared with
the PTHR. De14-PTHR displayed impaired trafficking and accumulated in endoplasmic reticulum. Signaling and activation of cAMP and
ERK by De14-PTHR was decreased significantly compared with PTHR. De14-PTHR acts as a functional dominant-negative by suppressing
the action of PTHR. Cells cotransfected with both receptors exhibit markedly reduced PTHR cell membrane expression, colocalization
withDe14-PTHRinendoplasmic reticulum,anddiminished cAMPactivation andERKphosphorylation inresponse tochallenge withPTH.
De14-PTHRformsheterodimers withPTHR,whichmayaccountforcytoplasmic retentionofPTHRinthepresenceof De14-PTHR.Analysis
of the PTHR heteronuclear RNA suggests that base-pair complementarity in introns surrounding exon 14 causes exon skipping and
accounts for generation of the De14-PTHR isoform. Thus De14-PTHR is a poorly functional receptor that acts as a dominant-negative of
PTHR trafficking and signaling and may contribute to PTH resistance.  2011 American Society for Bone and Mineral Research.
KEY WORDS: PTH RECEPTOR; ISOFORM; DOMINANT-NEGATIVE; ALTERNATIVE SPLICING; G PROTEIN–COUPLED RECEPTORS; MEMBRANE TRAFFICKING;
MAP KINASE; ADENYLYL CYCLASE
Introduction
T
ype I parathyroid hormone (PTH) and PTH-related peptide
receptor (PTHR) belong to family B, subfamily 1, of G protein–
coupled receptors (GPCRs). Other members include receptors
for secretin, vasoactive intestinal peptide, growth hormone–
releasing hormone, glucagon, glucagon-like peptide, pituitary
adenylyl cyclase–activating peptide, corticotropin-releasing
hormone, and calcitonin (CTR).
(1) The PTHR is expressed
predominantly in kidney and bone, where it mediates PTH
actions on calcium and phosphate homeostasis and bone
turnover, respectively.
(2)
In humans, the PTHR gene contains 15 exons
   coding a 593-
amino-acid, 7-transmembrane-domain (TMD) receptor.
(3,4)
Family B1 GPCRs are characterized by an exon-intron organiza-
tion that permits alternative splicing of specific critical domains
that have been shown in some instances to alter the function
of the resulting isoform.
(5) Some of these family B isoforms are
characterized by the deletion of regions encoding the seventh
TMD (TMD7).
(5–8) The biologic role of these isoforms is largely
unexplored, but studies with corticotropin-releasing hormone
receptor (CRHR) variants suggest that they could be cellular
response modulators affecting CRHR signaling.
(6) Several PTHR
isoforms, or transcripts consistent with receptor isoforms, have
been described.
(9–11) It has been suggested that presumptive
nonfunctional PTHR isoforms could be the source of pathologies
associated with PTH dysfunction, including some cases of
pseudohypoparathyroidism type Ib (PHPIb).
(12) Analysis of the
exon coding structure and promoter regions of the PTHR
gene or its mRNA, however, failed to disclose mutations.
(13–16)
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  The exon nomenclature and numbering for the PTHR are confusing. The literature and PubMed give 14 to 16 exons. Exon 1 is the first that includes the start site of
transcription and, as such, is not defined bythe start site oftranslation orthe start site ofthe mature protein. Aswith most genes, the data onthe true exon 1 (where
transcription starts) is incomplete. Evidence suggests that there are multiple forms of exon 1 that are tissue-specific. There is at least 1 exon before the exon
encoding the signal sequence, which is exon 2. Based on this consideration, there are tentatively 15 exons in the human, mouse, and rat PTHR genes. Additionally, a
preliminary description of the PTHR lacking helix 7 referred to it as De14-PTHR.ð12Þ For these reasons, we follow the same numbering.
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143The biologic behavior and functional consequence of alterna-
tively spliced PTHR forms on signaling and trafficking and their
effects onPTHRactionareunknown.Wenowshowtheexistence
of a PTHR isoform lacking TMD7, which is encoded by exon 14
(De14-PTHR), in human renal epithelial cells. We characterized
De14-PTHR and its actions as a modulator of PTHR. De14-PTHR
expression is primarily cytoplasmic, where it interacts with the
PTHR in endoplasmic reticulum, thereby reducing delivery of the
wild-type receptor to the cell membrane and simultaneously
promotingPTHRdownregulation.Nonetheless,someDe14-PTHR
is expressed at the plasma membrane, but the absence of TMD7
results in extracellular localization of C-terminal receptor tail.
Signaling via cAMP formation and p44/42 MAP kinase [extra-
cellular signal-regulated kinase (ERK)] phosphorylation were
decreased in response to PTH. De14-PTHR also decreases cAMP
and ERK responses when coexpressed with the fully active PTHR.
We conclude that De14-PTHR acts as a dominant-negative of
PTHR and causes PTH resistance.
Materials and Methods
Reagents
Polyclonal and monoclonal HA.11 and monoclonal antihistidine
(His)antibodieswereobtainedfromCovance(Berkeley,CA,USA).
Monoclonal anti-Flag antibody was purchased from Sigma
(St Louis, MO, USA). The phosphorylated ERK1/2 and total
ERK antibodies were obtained from Cell Signaling Technology
(Danvers, MA, USA). Polyclonal anti-lysosome-associated mem-
brane protein 2 (anti-LAMP-2) was obtained from Anaspec (San
Jose, CA, USA). Secondary antibodies Alexa-Fluor 488, Alexa-
Fluor546,Alexa-Fluor680,zeocin,blasticidin, andgeneticinwere
purchased from Invitrogen (Carlsbad, CA, USA). The endoplasmic
reticulum–selective, cell-permeant dye ER-Tracker Red (BODIPY
TR Glibenclamide) and the nuclear counterstain 4’,6-diamidino-
2-phenylindole (DAPI) were purchased from Invitrogen. Horse-
radish peroxidase (HRP)–conjugated goat antirabbit secondary
antibody was from Pierce (Rockford, IL, USA), and HRP-
conjugated sheep antimouse antibody was from GE Healthcare
(Piscataway, NJ, USA). Protease inhibitor mixture set I was from
Calbiochem (San Diego, CA, USA). Human PTH(1–34) and PTH(7–
34) were obtained from Bachem (Torrance, CA, USA). All other
reagents were from Sigma.
Cell culture
Renal proximal tubule cells were isolated from the urine of
normal subjects as described previously.
(17) These cells exhibit a
phenotype that includes expression of g-glutamyl transpepti-
dase, a characteristic brush-border enzyme and PTH-stimulated
cAMP.
(18) Briefly, urine samples were centrifuged for 15minutes
at 1500g at 48C, and pellets were washed twice with phosphate-
buffered saline (PBS). Cell RNA was isolated using guanidinium
thiocyanate–phenol–chloroform extraction (TRIZOL, Invitrogen)
according to the manufacturer’s instructions. Buccal epithelials
cellswereharvested withacotton swab,andRNA wasisolatedas
described previously. CHO-N10 cells, a subline of Chinese
hamster ovary developed in our lab,
(19) were cultured in Ham’s
F-12 medium supplemented with 10% fetal bovine serum (FBS),
100 units/mL of penicillin, 100mg/mL of streptomycin, and
10mg/mL of blasticidin. HEK-293 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS, 100 units/mL of penicillin, and 100mg/mL of
streptomycin. Also, 1.5% G418 was added to the latter medium
used for HEK-293 cells constitutively expressing the GFP-PTHR
(HEK-293R).
(19) Immortalized proximal tubule epithelial HK-2 and
HKC-8 cells from normal adult human kidney
(18) were cultured
in DMEM/F-12 50:50 medium supplemented with 10% FBS,
100 units/mL of penicillin, and 100mg/mL of streptomycin. Cells
were maintained at 378C in a humidified atmosphere of 5% CO2
Plasmid constructions
pcDNA3.1þ-HA-PTHR, pcDNA3.1þ-Flag-PTHR, pcDNA3.1þ-HA-
De14-PTHR, pcDNA3.1þ-Flag-De14-PTHR, pBudCE4.1þ-Flag-
PTHR-His, and pBudCE4.1þ-HA-De14-PTHR–hemagglutinin
(HA)–tagged human PTHR in pcDNA3.1 were constructed as
described previously.
(20)
pcDNA3.1þ-Flag-PTHR, pcDNA3.1þ-HA-De14-PTHR, and
pcDNA3.1þ-Flag-De14-PTHR
Flag-tagged PTHR was generated by converting the sequence
DKEAPTGS (residues 94 to 101) in exon E2 to DYKDDDDK of
Flag epitope.
(21) pcDNA3.1(þ)-HA-De14-PTHR was engineered
by using polymerase chain reaction (PCR) overlapping extension
for two-fragment assembly.
(21) Briefly, a 1.4-kb fragment from
amino acids 1 to 451, with incorporation of a HindIII restriction at
the 5’ site, was amplified by PCR using pcDNA3.1(þ)-HA-PTHR as
a template.
(19) A second fragment of 0.4-kb product from amino
acid 466 to the end of PTHR with incorporation of a 15-bp
extension at the 5’ site, which overlapped with the 3’ site of the
first fragment, and EcoRI at the 3’ site was amplified by PCR using
the sametemplateas forthefirstfragment synthesis.Thesecond
PCR was performed using the preceding two fragments as
templates. HA-De14-PTHR was subcloned into pcDNA3.1(þ).
pcDNA3.1(þ)-Flag-De14-PTHR was engineered as earlier except
that pcDNA3.1(þ)-Flag-PTHR served as the PCR template. The
accuracy of these constructs was confirmed by sequencing (ABI
PRISM 377, Applied Biosystems, Foster City, CA, USA).
pBudCE4.1þ-Flag-PTHR-His and HA-De14-PTHR-His were
obtained in the following manner: Flag-PTHR and HA-De14-
PTHR were amplified using the forward primer with NotI
restriction site (AGAAGAAGAAAGCGGCCGCATGGGGACCGCCC-
GGATC), and the reverse primer with BstBI restriction site
(CGGAGGAGAATTTCGAACATGACTGTCTCCCACTC). Purified PCR
fragments were cut by NotI and BstBI and subcloned into the
pBudCE4.1 before a polyhistidine-expressing region.
Transient transfection
Cells were grown to 50% to 60% confluence and transfected, as
indicated with 1mg of DNA per well in 6-well plates with HA-
PTHR, Flag-PTHR, HA-De14-PTHR, Flag-De14-PTHR, and EPAC,
Rab 5, Rab 7, Rab 11, and Arf 1
(22) (kindly provided by Dr J-P
Vilardaga) using FuGENE 6 (Roche, Indianapolis, IN, USA)
according to the manufacturer’s protocol. Experiments involving
transfection of PTHR isoforms, Rabs or Arf, alone or in
combination, were performed with constant amounts of each
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was expressed to keep constant the total amount of DNA. All
experiments were performed 48hours after transfection.
Immunoblot analysis
Transiently transfected cells with different combinations of PTHR
isoforms were lysed with Nonidet P40 (50mM Tris, 150mM NaCl,
5mM EDTA, 0.5% Nonidet P40) supplemented with protease
inhibitor mixture I and incubated for 30minutes on ice. Lysates
were centrifuged for 20minutes at 14,000g at 48C.
Total lysate proteins were analyzed by SDS-PAGE and
transferred to Immobilon-P membranes (Millipore, Billerica,
MA, USA) using the semidry method (BioRad, Hercules, CA,
USA). Nonspecific binding was blocked by incubating the
membranes in 5% nonfat milk in Tris-buffered saline plus 0.1%
Tween-20 (TBST) for 1 hour at room temperature, followed by
overnight incubation with the indicated antibodies (monoclonal
anti-Flag and anti-HA antibodies, polyclonal anti-phospho p42/
44 and anti-p42/44 antibodies at 1:1000) at 48C. The membranes
then were washed and incubated at room temperature for
1 hour in horseradish peroxidase (HRP)–conjugated goat anti-
rabbit IgG or sheep antimouse IgG diluted 1:2000. Protein bands
were visualized with a luminol-based enhanced chemilumines-
cence substrate.
Receptor binding
Receptor binding was measured as described previously
(19,23)
using high-pressure liquid chromatography–purified [
125I]
[Nle
8,18,Tyr
34]-hPTH(1–34)NH2. Different concentrations of
PTH(1–34) or vehicle were added to fresh culture medium
bathing confluent cells seeded on 24-well plates. HEK cells were
incubated with approximately 100,000 cpm of [
125I][Nle
8,18,-
Tyr
34]-hPTH(1–34)NH2 on ice for 2.5hours. Nonspecific binding
was determined either by parallel incubation of nontransfected
cells with [
125I][Nle
8,18,Tyr
34]-hPTH(1–34)NH2 or measured in
parallel experiments carried out in the presence of 1mM
unlabeled PTH(1–34) and subtracted from total binding to
calculate specific binding. After incubation, cells were washed
twice with cold PBS and solubilized in 0.2N NaOH. Cell surface–
bound [
125I][Nle
8,18,Tyr
34]-hPTH(1–34)NH2 was counted by g
spectrometry. Receptor number (Bmax) was calculated by
nonlinear regression using a homologous binding algorithm
(Prism, GraphPad, San Diego, CA, USA).
(24)
Immunofluorescence confocal microscopy
Cells were seeded on coverslips and allowed to settle overnight.
Then 100nM PTH(1–34) was added for the indicated times,
and cells were fixed with 4% paraformaldehyde. Permeabilized
samples were treated for 10minutes with 0.1% Triton X-100
in PBS. Nonspecific binding was blocked with 5% goat serum
in PBS for 1 hour at room temperature. Polyclonal anti-HA and
anti-LAMP-2 and monoclonal anti-Flag or anti-His antibodies
were added for 1 hour at room temperature.
After three PBS washes, samples were incubated with Alexa-
Fluor 488 or Alexa-Fluor 546 (1:1000) for 1 hour at room
temperature. 4’,6-Diamidino-2-phenylindole (DAPI) was used to
stainthecellnucleusinsomesamples.Slidesweremountedwith
aqueous mounting medium and examined by confocal micro-
scopy using an Olympus FluoView 1000 (Olympus Corp., Lake
Success, NY, USA).
Receptor internalization
PTHR internalization was measured in cells transiently trans-
fected with HA-PTHR, HA-De14-PTHR, or HA-PTHR plus Flag-
De14-PTHR. Cells were seeded on poly-D-lysine-coated 24-well
plates. Confluent cells were treated with PTH and fixed with 3.7%
paraformaldehyde at room temperature. After 3 washes with
PBS, cells were blocked with 1% bovine serum albumin (BSA) for
45minutes and incubated with polyclonal anti-HA antibody for 1
hour at room temperature. Cells then were washed with PBS,
reblocked with 1% BSA for 15minutes, and incubated with anti-
IgG conjugated with alkaline phosphatase (ELISA protocol) or
antirabbit Alexa Fluor 680nm (flow cytometry protocol) for
1houratroomtemperature.Afterwashing,alkalinephosphatase
substrate was added for 30minutes, 100mL of the reaction
mixture was transferred to a 96-well plate, and absorbance was
measured at 405nm (ELISA protocol).
Fluorescence resonance energy transfer (FRET)
HEK-293 cells were transiently transfected with the cAMP
biosensor EPAC.
(25) Cells plated on poly-D-lysine-coated glass
25-mm coverslips were maintained in HEPES/BSA buffer.
Coverslips were mounted on the stage of an Olympus IX 71
microscope equipped with a 60  oil-immersion objective and a
monochromator (TILL Photonics, Gra ¨felfing, Germany). FRET was
monitored as the emission ratio of YFP and CFP with SlideBook
(IntelligentImagingInnovations,Inc.,Denver, CO,USA).FRETwas
calculatedandnormalizedasdescribedpreviously.
(26)Resultsare
shown as the normalized mean (nFRET) SEM.
Semiquantitative RT-PCR
Total cell RNA was isolated with TRIZOL. Then 400ng of RNA was
reverse-transcribed, and the resulting cDNA was amplified using
a commercial kit (Titanium One-Step RT-PCR, Clontech, Palo Alto,
CA, USA) with the primers GTCCAGATGCACTATGAG (forward)
and GACATTGGTCACACTTGT (reverse), corresponding to nucleo-
tides 1315 to 1332 and 1507 to 1524, respectively, in the human
PTHR gene (GenBank Accession Number NM 000316). GAPDH
primers GAGTCAACGGATTGGTCGT (forward) and TTGATTTTG-
GAGGGATCTCG (reverse) were used for GAPDH coamplification
as an internal control. PCR products were separated on 2%
agarose gels, and bands were visualized by ethidium bromide
staining. Quantitative PCR (qPCR) experiments used the same
primers.TaqManMGBprobeswereobtainedbyAssay-by-Design
(Applied Biosystems). PTHR VIC-TCGCAATCATATACTGTTTCT-
GCAA-TAMRA and De14-PTHR 6FAM-TCAACTCCTTCCAGG-
TACAAGCTGAGA-TAMRA cDNA was synthesized using AccuScript
High Fidelity RT-PCR System (Stratagene, La Jolla, CA, USA) with
random hexamer primers, and qPCR was carried out with an
ABI PRISM 7500 System (Applied Biosystems) following the
manufacturer’s instructions.
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Colocalization of De14-PTHR within cytoplasmic compartments
wasanalyzed withImageJ
(27) tocalculate the Pearson coefficient,
whichisdefinedhereastheratioofthecovarianceoftheredand
green color images divided by the product of the standard
deviation of the normalized image intensities.
Statistics
Data are presented as the mean SE, where n indicates the
number of independent experiments. Multiple comparisons
were evaluated by one- or two-way analysis of variance with
posttest repeated measures analyzed by the Bonferroni
procedure (Prism, GraphPad). Differences greater than p .05
were assumed to be significant.
Results
Expression of De14-PTHR in human cells
Previous data from family B1 GPCRs suggested the possibility of
an alternatively spliced form of the PTHR lacking TMD7.
(5–8,12) To
identify a PTHR isoform with these characteristics in human cells,
mRNA from renal tubule cells collected from urine and/or buccal
epithelial cells was analyzed. Amplification by RT-PCR generated
a fragment of the expected 217 bp indicating PTHR gene
expression (Fig. 1A). Notably, an additional smaller product of
171 bp was detected in renal and in some buccal mRNA samples
(Fig. 1A), consistent with the size of small PTHR transcripts
reported in rat kidney cells.
(9) The smaller band was sequenced
and corresponds to the PTHR mRNA with an in-frame 42-bp
deletion corresponding to exon 14, which encodes most of
TMD7 (data not shown). No mutations were noted in the coding
regions or in the corresponding donor and acceptor splice sites.
HK-2 renal tubular epithelial cells expressed both PTHR and
De14-PTHRforms ofthe receptor, whereas HKC-8 cells expressed
only wild-type PTHR. Full-length and truncated PTH receptors
specifically designed were transfected in HEK-293 as a control
(Fig. 1A, bottom). The presence of De14-PTHT was corroborated
by qPCR using probes specific for this alternatively spliced
variant (Fig. 1B).
De14-PTHR topology
We analyzed the predicted topology of the De14-PTHR and
compared it with the wild-type receptor using the TMHMM
algorithm (http://workbench.sdsc.edu), which predicts trans-
membrane helices and inverted-loop regions based on a
hidden Markov model.
(28) Whereas the PTHR displayed the
expected heptahelical protein conformation with an intracellular
C-terminus, the De14-PTHR folds with 100% probability as a
6-transmembrane-spanning receptor without TMD7 and with
the C-terminus located extracellularly (Fig. 2A). To test this
prediction, we generated De14-PTHR with a polyhistidine (6 
His) tag at the C-terminus. The localization of De14-PTHR was
determined by confocal microscopy with CHO-N10 cells. In
nonpermeabilized cells, PTHR was undetectable, consistent with
theinaccessibleC-terminalepitopetaginthecytoplasm(Fig.2B).
Under the same conditions, distinct De14-PTHR cell surface
fluorescence is present. In permeabilized cells, both De14-PTHR
and PTHR immunofluorescence are observed (Fig. 2B). These
findings are compatible with an extracellular localization of the
C-terminus of De14-PTHR.
Cytoplasmic De14-PTHR expression
To assess the subcellular distribution of De14-PTHR, we
transiently transfected HEK-293 cells with truncated or full-
length PTH receptors. Confocal microscopy shows that HA-PTHR
clearly localizes to the cell membrane (Fig. 3A). Similar results
wereobtainedinCHO-N10cellsandwithFlag-PTHRorGFP-PTHR
(images not shown). In contrast, Flag-De14-PTHR exhibited
conspicuously lower cell surface expression but intense
cytoplasmic abundance (Fig. 3A). HA-De14-PTHR also was
predominantly cytoplasmic with little plasma membrane
expression (image not shown).
We next characterized the influence of De14-PTHR on PTHR
distribution. Truncated and full-length receptors were cotrans-
fected in HEK-293 and CHO-N10 cells. Whereas PTHR is not
normally observed in cytoplasm (Figs. 2B and 3), strong
cytoplasmic colocalization of GFP-PTHR and Flag-De14-PTHR
was observed in HEK-293 cells (Fig. 3A). Similar results were
obtained in CHO-N10 cells (images not shown). These findings
suggest that De14-PTHR causes retention of PTHR in the
cytoplasm.
To determine if the interference by De14-PTHR of membrane
targetingisspecifictothePTHR,weexaminedtheeffectofDe14-
PTHR on the localization of the calcitonin receptor (CTR), a family
B receptor with ahelix 7isoform, and the b2-adrenergic receptor,
a prototype family A receptor. HA-CTR or GFP-b2-adrenergic
receptorswerecotransfected withFlag-De14-PTHR.BothHA-CTR
and GFP-b2-adrenergic receptors localized to the plasma
membrane and did not colocalize with De14-PTHR in the
cytoplasm (Fig. 3A). When cotransfected with GFP-PTHR, the HA-
CTR showed no effects on PTHR expression at the cell membrane
(data not shown). Thus the retention of PTHR in the cytoplasm is
specific for De14-PTHR.
The extent of plasma membrane De14-PTHR expression
was quantified by ligand-binding experiments. PTHR exhibited
10-fold higher expression than the De14-PTHR with 1.60 10
6
PTHRs/cell compared with 0.15 10
6 De14-PTHRs/cell (Fig. 3B
and Supplemental Fig. S1).
In the presence of De14-PTHR, cell surface expression of PTHR
decreased by 56% (0.7 10
6 receptors/cell). These findings
confirm that De14-PTHR suppresses PTHR membrane expres-
sion. Considering the effects of the TMD7 on PTHR topology, we
turned our attention to whether this truncation affects inherent
affinity for PTH. Scatchard analysis of ligand-binding showed Kd
values of 5nM for PTHR, 40nM for De14-PTHR, and 12nM when
both receptors were cotransfected.
We performed coimmunoprecipitation experiments to deter-
mine directly whether De14-PTHR and PTHR interact. Immuno-
precipitation ofthe full-length receptor and immunodetection of
PTHR or De14-PTHR showed that both receptors homo- or
heterodimerize, respectively (Fig. 3C). The reverse experiment,
where the truncated De14-PTHR was immunoprecipitated and
the PTHR or De14-PTHR was immunoblotted exhibited compar-
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PTHR heterodimerization, we also observed PTHR homodimer-
ization (Fig. 3C). Together these results show that De14-PTHR
interacts directly with PTHR.
To determine the dynamic behavior of De14-PTHR and PTHR
and their trafficking response to PTH, we analyzed receptor
internalization by an ELISA assay using nonpermeabilized HEK-
293 cells. As shown in Fig. 3D, the PTHR was efficiently
internalized 30minutes after PTH(1–34). De14-PTHR membrane
expression was conspicuously lower than that of the PTHR and
did not appreciably internalize on PTH stimulation (Fig. 3D).
We next examined De14-PTHR effects on PTH-induced
internalization of the PTHR. De14-PTHR decreased PTHR
membrane-delimited expression by 52% (Fig. 3D). PTH induced
proportionately similar PTHR internalization in the presence or
absence of De14-PTHR (Fig. 3D). Similar results were obtained by
flow cytometry (data not shown). These findings suggest that
De14-PTHR does not affect internalization of the reduced subset
of membrane-delimited PTHR.
Retention of De14-PTHR in the endoplasmic reticulum
The difference between PTHR and De14-PTHR subcellular
localization led us to investigate the intracellular compartmen-
talization of De14-PTHR. We performed confocal microscopy to
determine the identity of endosomes containing De14-PTHR in
HEK-293 cells transfected with either green fluorescent protein
(GFP)–tagged Rab5, -7, or -11 or Arf 1, GTPases that control
trafficking of early and late, recycling, and Golgi network
endosomes, respectively. Modest levels of De14-PTHR were
found in Rab11
þ and Arf1
þ compartments, corresponding to
pericentriolar recycling endosomes and the trans-Golgi network
(Fig. 4 and Table 1). No significant localization of De14-PTHR
was observed with Rab5
þ or -7
þ early and late endosomes,
respectively (Fig. 4 and Table 1). To determine if De14-PTHR is
targeted to the endocytic degradative pathway or endoplasmic
reticulum (ER), we used a lysosomal-associated membrane
protein (LAMP-2) antibody or a fluorescent ER-Tracker, respec-
tively,inHEK-293cellstransfectedwithHA-De14-PTHR.Although
Fig. 1. PTHR isoform in human cells. (A) mRNA was extracted from renal (kid) and buccal (buc) epithelial cells of two normal subjects or HK2, HKC-8, and
HEK-293 cells lines transfected with De14-PTHR (e14) and/or PTHR. (B) qPCR analysis of mRNA isolated from HKC-8 or HK2 cells. DRn¼change in
normalized reporter signal. Representative samples of three to five independent determinations are shown. Assays were performed as described in
‘‘Materials and Methods.’’
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þ lysosomes, extensive
De-14PTHR was observed within ER (Fig. 4 and Table 1). These
results, along with the previous findings showing limited De14-
PTHR expression at the cell surface, suggest an early impairment
of De14-PTHR trafficking to the membrane and retention within
theER.Incontrast,PTHRisnotdetectableinRab5,-7,or-11,Arf1,
LAMP-2-positive compartments or in ER (Supplemental Fig. S2).
Thus, under resting conditions, the PTHR is found only at the
cell membrane. However, in the presence of De14-PTHR,
considerable ER accumulation of PTHR is observed (Fig. 5A).
De14-PTHR decreases PTHR protein expression
DecreasedcellmembraneDe14-PTHRexpressioncombinedwith
cytoplasmic accumulationraisedthepossibilitythattheseeffects
could be due to decreased protein synthesis alone or in
combination with increased receptor degradation. Indeed, we
observed decreased De14-PTHR protein expression levels
compared with PTHR (Fig. 5B). Moreover, cotransfection of
De14-PTHR impaired PTHR expression (Fig. 5B). Notably, no
differences in PTHR mRNA expression were observed in cells co-
Fig. 2. Orientation of De14-PTHR C-terminus. (A) Prediction of PTHR and De14-PTHR topology of transmembrane helices and inverting loop regions. The
protein sequences of PTHR and De14-PTHR were analyzed with the TMHMM program (http://workbench.sdsc.edu) to predict TMD and intracellular/
extracellular loops. Red represents TMD, the intracellular loops are represented in blue, and the extracellular loops are shown in pink. (B) Orientation of
the C-terminus of PTHR and De14-PTHR overexpressed in CHO-N10 cells was assayed by confocal microscopy. Cells transiently transfected with PTHR or
De14-PTHRlabeled at theC-terminus with a polyhistidinetag were eithernot permeabilized with Triton X-100 (top panel) or permeabilized (bottom panel)
before addition of specific antibody against histidine. DAPI staining was used to identify the nuclei. Similar results were obtained from multiple
independent experiments.
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in HEK-293 and COS-7 cells and by PCR (data not shown).
Net receptor protein expression is a balance between
synthesis and degradation. To test the hypothesis that
proteasome- or lysosome-dependent degradative mechanisms
contribute to diminished De14-PTHR protein levels, HEK-293
cells transfected with De14-PTHR were treated with MG-132 or
chloroquine, proteasome and lysosome inhibitors, respectively.
Fig. 3. De14-PTHRlocalizesat thecytoplasmandinteractswithPTHR.(A) HEK-293cellsweretransiently transfectedwithHA-PTHR,HA-calcitonin receptor
(CTR),GFP-b2-adrenergicreceptor,and/orFlag-De14-PTHR,grownonglasscoverslipsfor48hours,fixed,andpermeabilizedasdescribedin‘‘Materialsand
Methods.’’ HA-tagged PTHRandCTR weredetectedusinga specificpolyclonalprimaryantibodyfor HA(1:1000)andAlexa-Fluor488(1:2000) (green).Flag-
tagged De14-PTHR was detected using a specific primary antibody for Flag (1:1000) and Alexa-Fluor 546 (1:2000) (red). Right panels show the merged
images. Colocalization of the green and red labels is shown in yellow. Representative images obtained by confocal microscopy of at least three
experiments are illustrated. (B) Number of receptors (Bmax) in HEK-293 cells transiently cotransfected with HA-PTHR, or Flag-De14-PTHR and pcDNA3.1, or
HA-PTHR and Flag-De14-PTHR was calculated as described in ‘‘Materials and Methods.’’ Data are the mean triplicate determinations and are summarized
as SE of three independent experiments.
  p<.01;
 p<.05 versus PTHR. (C) HEK-293 cells stably transfected with HA-PTHR (HEK-R) were transiently
transfected with or without Flag-PTHR or Flag-De14-PTHR as indicated. Cells were lysed after 24hours, and the HA-PTHR/Flag-PTHR and HA-PTHR/Flag-
De14-PTHR dimers were immunoprecipitated (IP) using the HA.11 monoclonal affinity matrix. Immune complexes were immunoblotted (IB) with anti-HA
or anti-Flag antibodies as described in ‘‘Materials and Methods.’’ Total lysates were immunoblotted with anti-HA or anti-Flag antibodies as a transfection
control. Representative images of at least three independent experiments are shown. (D) HEK-293 cells on 24-well plates were transiently transfected
with HA-PTHR, HA-De14-PTHR and pcDNA3.1, or HA-PTHR and Flag-De14-PTHR. After 48hours, the cells were incubated in the presence or absence of
PTH(1–34) for 30minutes. Receptor internalization was assayed by ELISA as described in ‘‘Materials and Methods.’’ Similar results were obtained in three
independent experiments.
   p<.001;
  p<.01 versus –PTH.
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blockade (t1/2¼5.39hours; Fig. 5C). Lysosome inhibition did
not affect De14-PTHR degradation (data not shown). Within
experimental error, neither proteosomal nor lysosomal degrada-
tion of PTHR was detected (data not shown). Thus De14-PTHR is
metabolized by ubiquitination and targeted to proteasomes.
When De14-PTHR was cotransfected with PTHR, however, PTHR
protein levels that were diminished in the presence of De14-
PTHR now increased toward basal expression values when
pretreated with the proteasome inhibitor (t1/2¼2.0hours;
Fig. 5C). Again, lysosomal inhibition was without effect (data
not shown).
De14-PTHR inhibits PTHR signaling
As shown earlier, the absence of TMD7 impairs membrane
localization of De14-PTHR and alters its subcellular distribution,
suggesting that its biologic response to PTH likely would be
compromised. We therefore characterized the signaling cap-
ability of De14-PTHR by measuring cAMP and ERK responses to
PTH, two well-established and independent signaling mechan-
isms. Using the cAMP FRET biosensor EPAC (exchange protein
directly activated by cAMP), we observed a rapid increase of
cAMP formation (denoted as the CFP/YFP ratio) triggered by
PTH(1–34) in HEK-293 cells transfected with PTHR (t1/2¼0.42 
Fig. 4. Internalized De14-PTHR localizes in the endoplasmic reticulum (ER). HEK-293 cells were transiently cotransfected with Flag-De14-PTHR and GFP-
Rab 5, GFP-Rab 7, GFP-Rab 11, or GFP-Arf 1 as indicated, grown on glass cover slips for 48hours, fixed, and permeabilized as described in ‘‘Materials and
Methods.’’ Flag-tagged De14-PTHR was detected using a specific primary antibody for Flag (1:1000) and Alexa-Fluor 546 (1:2000) (red) or Alexa-Fluor
488 (1:2000) (green). Lysosomes were detected using a rabbit polyclonal anti-LAMP-2 antibody (1:1000) and Alexa-Fluor 488 (1:2000) (green), and the ER
was detected using ER-Tracker Red. Right panels show the merged images. Colocalization of the green and red labels is shown in yellow. The cells were
examined by confocal microscopy. Representative images of at least three independent experiments are shown.
150 Journal of Bone and Mineral Research ALONSO ET AL.0.05minutes; Fig. 6A). The longer t1/2 of 0.86 0.16minutes for
the De14-PTHR suggests that cAMP signaling is impaired
(Fig. 6A). Additionally, we observed limited ERK phosphorylation
in response to PTH(1–34) in CHO-N10 cells transfected with
De14-PTHR compared with PTHR (Fig. 6B).
Because De14-PTHR affects PTHR membrane expression and
subcellulardistribution,wepredictedthatthetruncatedreceptor
also disrupts PTHR signaling. To test this idea, we measured
cAMP activation and ERK phosphorylation in HEK-293 cells
transiently transfected with HA-PTHR with or without Flag-De14-
PTHR. Cotransfection of PTHR with Flag-De14-PTHR strongly
inhibited PTH(1–34)-triggered cAMP formation, as determined
by FRET (De14-PTHRþPTHR t1/2¼0.65 0.08minutes versus
PTHR t1/2 0.42 0.05minutes; Fig. 6A). The inhibitory action of
De14-PTHR was specific in that De14-PTHR did not interfere with
norepinephrine-stimulated cAMP formation by the b2-adrenergic
receptor (t1/2¼1.157 0.008; t1/2¼b2-adrenergic receptorþ
De14-PTHR¼1.190 0.015, NS). Furthermore, cotransfection of
De14-PTHR with PTHR abolished PTH-induced ERK phosphoryla-
tion (Fig. 6B).
Discussion
This study reveals the presence of a novel, alternatively spliced
PTHR isoform in renal tubular epithelial cells and characterizes its
trafficking and signaling, as well as its structural and functional
interactions with the full-length PTHR. The low abundance of
De14-PTHR at the plasma membrane underscores the impor-
tance of the TMD7 for proper receptor targeting and integration
at the cell surface and for membrane retention. The structural
basis for the critical role of this domain for accurate membrane
receptor localization is not well understood. Failure of receptor
export or decreased stability at the membrane could account for
reduced De14-PTHR cell surface expression. A GFF motif within
the conserved region of TMD7 is indispensable for CRHR
membrane expression.
(8) This motif, which also is present in the
PTHR, may be essential to form the seventh hydrophobic helix,
and in its absence, the consequent protein misfolding does not
allow the receptor to be transported through the endoplasmic
reticulum (ER).
(8) Other checkpoint motifs described for
vasopressin V2, angiotensin II, dopamine D1, V1b/V3, and b2-
adrenergic receptors are necessary for ER-to-Golgi transfer.
(29–33)
However, these motifs are absent in the PTHR C-terminus.
Alternatively, excision of the De14-PTHR TMD7 could generate
a motif that inhibits transit of the truncated receptor to the
membrane by unmasking a cryptic retention signal, as observed
in g-aminobutyric acid (GABA) receptors.
(34)
Dimerization is required for some GPCRs to be transported to
theplasmamembrane.
(35)TheC-terminusoftheGABABreceptor,
for instance, is critical to promote receptor dimerization. More
specifically, heterodimerization of GABAB receptors uses the
C-terminal retention motif RXR(R),
(36) which also is present in
the PTHR. It is thus possible that the nascent PTHR is formed as a
dimer that dissociates in the ER before transport to the plasma
membrane. Recent evidence demonstrates that the PTHR is
targeted to the plasma membrane as a dimer and dissociates on
bindingPTH.
(37)PTHR–De14-PTHRheterodimers maynotbeable
to dissociate, accounting for the cytoplasmic accumulation of
PTHR in the presence of De14-PTHR. Heterodimerization of
CTR with its truncated isoform, a process that involves the
C-terminus, prevents transport of the receptor to the cell
surface.
(5) The aberrant orientation of the De14-PTHR C-terminus
and protein misfolding could act on the PTHR in a similar
manner, causing accumulation in the ER and retention of the
full-length PTHR, thereby impairing its transport to the cell
membrane.
In addition to lower expression at the cell surface, De14-PTHR
exhibits lower affinity for PTH. Thus TMD7 influences PTH
binding, as it does calcitonin binding to CTR,
(5) although TMD7 is
not necessary for agonist binding to CRH-R1d.
(6) Hence similar
motifs are capable of exerting distinct roles on ligand affinity to
family B GPCRs. Compared with their full-length receptor
counterparts, CRHR and CTR isoforms lacking the seventh
TMD exhibited impaired ligand-stimulated cAMP formation
(6,38)
or limited coupling to Gs, Gq, Gi, and Go in the case of the CRHR
isoform, CRH-R1d.
(6) The fact that the t1/2 for adenylyl cyclase
activation by PTH was reduced suggests that De14-PTHR
coupling to adenylyl cyclase is compromised. This kinetic
manifestation arises as a consequence of decreased activated
(receptor-ligand) complex. By contrast, normalizing the extent of
cAMP formation to receptor number indicates that there is no
change in De14-PTHR intrinsic activity (ie, the magnitude of the
response). Similar observations were reported for the truncated
isoform of CTR, which failed to mobilize intracellular calcium or
phosphorylate ERK.
(8) Thus the reduced signaling by De14-PTHR
is likely due to a combination of the 10-fold lower expression of
De14-PTHR at the cell membrane and diminished ligand affinity.
Several key signaling motifs situated within the PTHR
intracellular tail are inaccessible in the De14-PTHR owing to
its extracellular location. This also could contribute importantly
to the diminished signaling by the De14-PTHR. For instance,
Table 1. Cytoplasmic De14-PTHR Accumulates in Endoplasmic Reticulum (ER)
Arf 1 Rab 5 Rab 7 Rab 11 LAMP-2 ER
r,%
PTHR 0.27 0.07 0.39 0.07 0.36 0.06 0.55 0.05 0.29 0.02 0.16 0.03
De14-PTHR 0.55 0.16 0.29 0.27 0.34 0.16 0.55 0.17 0.25 0.09 0.70 0.08
 
Note: The Pearson correlation coefficient r was calculated with ImageJ.(27) The calculation shows colocalization of De14-PTHR with Arf 1 (Golgi
apparatus), Rab 5 (early endosomes), Rab 7 (late endosomes), Rab 11 (recycling endosomes), LAMP-2 (lysosomes), and endoplasmic reticulum (ER).
Technical details are described in ‘‘Materials and Methods.’’
 p<.5 significant positive colocalization. n¼5 to 8 independent observations for each condition.
DOMINANT-NEGATIVE ACTION OF A TRUNCATED PTHR ISOFORM Journal of Bone and Mineral Research 151Fig. 5. De14-PTHRdecreasesPTHRproteinlevels.(A)HEK-293cellsweretransientlytransfectedwithGFP-PTHR Flag-De14-PTHRasindicatedandgrown
on glass cover slips for 48hours. ER was detected using ER-Tracker Red. Cells were examined by confocal microscopy. Right panels show the merged
images. Colocalization of the green and red labels is shown in yellow. Representative images of at least three independent experiments are shown. (B)
CHO-N10 cells were transiently cotransfected with HA-PTHR and Flag-De14-PTHR or the empty vector pcDNA3.1. After 24 or 48hours of transfection,
mRNA and protein were extracted, and semiquantitative and immunoblot assays were performed as described in ‘‘Materials and Methods.’’ (C) HEK-293
cells were transiently transfected with Flag-De14-PTHR, HA-PTHR, or Flag-De14-PTHRþHA-PTHR (1.5 and 0.5mg) for 24hours and treated with the
proteasome inhibitor MG-163 for 2 to 8hours. Total lysates were extracted and immunoblotted as described in ‘‘Materials and Methods.’’ HA and Flag
epitopes were detected using specific primary antibodies (1:1000) and HRP-tagged antibodies (1:2000). Data illustrate three or four independent
experiments performed in triplicate and were analyzed by two-way ANOVA.
  p<.01;
 p<.05 versus PTHR.
152 Journal of Bone and Mineral Research ALONSO ET AL.mutations in the juxtamembrane region of the C-tail between
amino acids 468 and 491 of the PTHR disrupt Gßg interactions
with the receptor, block PTH signaling by phospholipase C and
ERK, and markedly reduce cAMP signaling.
(39) Furthermore, the
PTHR C-terminus contains several proline-rich motifs that are
essential to trigger ERK phosphorylation by c-Src and arrestin
activation
(36) thatwouldnot beavailableinDe14-PTHR.Negative
and positive regulators of PTHR endocytosis that are present
withintheupstreamregionofthePTHRintracellulartail
(40)would
no longer exert their actions in the De14-PTHR. Finally,
cytoplasmic PDZ scaffolding proteins such as NHERF1 that
interact with the C-terminus and regulate signaling and PTHR
trafficking
(19,23,41–43) would be incapable of exerting their
modulatory actions on the De14-PTHR. Thus the redirected
extracellular C-terminus of the De14-PTHR, in combination with
limited De14-PTHR expression at the plasma membrane also
may contribute to the reduced signaling of this naturally
occurring receptor isoform.
Protein synthesis is regulated at multiple levels during
transcription and translation. Our results show that diminished
PTHR expression is not due to downregulation at transcriptional
levels because similar PTHR mRNA expression was observed in
the presence or absence of De14-PTHR. This suggests possible
posttranscriptional modulation of PTHR expression by the
truncated receptor. Proteins localized at the plasma membrane
usually are degraded by lysosomes,
(44) whereas misfolded
proteins that accumulate in cytoplasmic compartments such
as the ER, the ER/Golgi intermediate compartment (ERGIC), or
Fig. 6. De14-PTHR impaired PTHR-induced cAMP activation and ERK phosphorylation triggered by PTH(1–34). (A) HEK-293 cells transiently transfected
with HA-PTHR, EPAC and pcDNA3.1, and/or Flag-De14-PTHR were treated with 100nM PTH(1–34) for 5minutes. cAMP accumulation was measured by
FRET, as described in ‘‘Materials and Methods.’’ Data are the average of triplicate independent determinations. (B) CHO-N10 cells transiently transfected
with different combinations of HA-PTHR, pcDNA3.1, and/or Flag-De14-PTHR as indicated were grown on 6-well plates for 48hours and serum-starved for
2hours before stimulation with 100nM PTH(1–34) for 10minutes. Total lysates were extracted, and immunoblotting was performed as described in
‘‘Materials and Methods.’’ Phospho-p44/42, total p44/42, and HA and Flag epitopes were detected using specific primary antibodies (1:1000) and HRP-
taggedantibodies(1:2000).Upperpanelsshowrepresentativeimmunoblotimages.Dataillustratethreeindependentexperimentsperformedintriplicate.
 p<.05 versus control.
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the ubiquitination- and proteasome-dependent ER-associated
degradation pathway (ERAD) or by mechanisms that remain
unknown, respectively.
(45,46) De14-PTHR could interact with
PTHR in the ER, ERGIC, or Golgi compartments, leading to its
retention and subsequent proteolysis by proteasome degrada-
tion. The response to PTH, as in HK-2 cells, could be diminished
owingtoexpressionoftheDe14-PTHRcomparedwithothercells
that do not express this isoform.
Exon skipping is a common mechanism of genomic
combinatorial control of alternative splicing.
(47) The introns
flankingtheskippedexontypicallypossessspecificsequences,in
addition to the canonical splice donor and acceptor sequences
that regulate where skipping occurs. A G-rich region distal to the
5’ splice donor and a C-rich region proximal to the 3’ splice
acceptor play key roles in this process.
(48) These regions form a
stem-loop structure in the heteronuclear RNA (hnRNA) that
makes it possible to bring, in the case of the PTHR, exons 13 and
15 close together and permit the deletion of exon 14. The small,
42-bp size of exon 14 makes it an ideal candidate for exon
skipping. Ina stretchof11bases,8 are complementary. Moreover,
although there is significant complementarity between the 5’
G-rich region upstream of the exon 14 and the C-rich region
downstream of exon 14, it is not perfect. This could permit small
nuclear ribonuclear proteins (snRNPs) that regulate the splicing
process to promote inclusion or exclusion of exon 14.
Pseudohypoparathyroidism type 1b (PHP1b) is characterized
by renal PTH resistance accompanied by hypocalcemia,
hyperphosphatemia, and elevated serum PTH levels.
(49) Defec-
tive genomic imprinting of GNAS accounts for most cases of
familial PHP1b. However, autosomal dominant inheritance does
not explain the majority of cases of PHP1b
(50) or a significant
portion of PHP1a.
(51) Regulated expression of De14-PTHR by
snRNPs might affect PTHR abundance in the kidney. Accumula-
tionofDe14-PTHRincellsexpressingPTHRfromdifferenttissues,
we propose, inhibits signaling and function of the full-length
receptor and could explain PTH resistance in some cases of
pseudohypoparathyroidism and perhaps in other forms of PTH
or PTH-related protein (PTHrP) resistance of unknown origin.
In summary, De14-PTHR is present in renal tubular epithelial
cells, where it exhibits reduced anchorage to the plasma
membrane, mislocation of its C-terminus to the extracellular
compartment, and accumulation in the ER and displays impaired
cAMP and ERK signaling. Moreover, De14-PTHR decreases PTHR
cell surface expression and protein levels, forms heterodimers
with PTHR, and also inhibits PTHR-mediated cAMP and ERK
signaling. Exon 14 deletion may arise from a regulated but as yet
poorly understood pattern of hnRNA complementarity common
to family B receptors.
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